| Assay ID | Title | Year | Journal | Article |
|---|
| AID1881820 | Protac activity against VHL/EGFR deletion 19 mutant in human HCC827 cells relative to control | 2022 | European journal of medicinal chemistry, Jan-05, Volume: 227 | VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives. |
| AID1881821 | Protac activity against VHL/EGFR L858R mutant in human HCC827 cells | 2022 | European journal of medicinal chemistry, Jan-05, Volume: 227 | VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives. |
| AID1704977 | Protac activity at VHL/EGFR del19 mutant in human HCC827 cells assessed as induction of EGFR degradation measured after 24 hrs by Western blot analysis | 2020 | European journal of medicinal chemistry, Dec-15, Volume: 208 | Discovery of potent small molecule PROTACs targeting mutant EGFR. |
| AID1582400 | Protac activity at VHL/EGFR exon 19 deletion mutant in human HCC827 cells assessed as induction of EGFR degradation at 1 to 10 uM treated 8 hrs post serum starvation measured after 16 hrs by Western blot analysis | 2020 | Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
| Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders. |
| AID1582388 | Protac activity at VHL/EGFR exon 19 deletion mutant in human HCC827 cells assessed as reduction in EGFR autophosphorylation up to 10 uM treated 8 hrs post serum starvation measured after 16 hrs by Western blot analysis | 2020 | Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
| Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders. |
| AID1880577 | PROTAC activity at VHL/wild type EGFR in human OVCAR-8 cells assessed as EGFR degradation measured after 24 hrs by Immunoblotting analysis | 2022 | Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
| Exploring Degradation of Mutant and Wild-Type Epidermal Growth Factor Receptors Induced by Proteolysis-Targeting Chimeras. |
| AID1881819 | Protac activity against VHL/EGFR deletion 19 mutant in human HCC827 cells | 2022 | European journal of medicinal chemistry, Jan-05, Volume: 227 | VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives. |
| AID1582399 | Protac activity at VHL/EGFR L858R mutant in human H3255 cells assessed as induction of EGFR degradation up to 500 nM treated 8 hrs post serum starvation measured after 16 hrs by Western blot analysis | 2020 | Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
| Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders. |
| AID1582398 | Protac activity at VHL/EGFR exon 19 deletion mutant in human HCC827 cells assessed as induction of EGFR degradation up to 500 nM treated 8 hrs post serum starvation measured after 16 hrs by Western blot analysis | 2020 | Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
| Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders. |
| AID1880578 | PROTAC activity at VHL/EGFR Del19 mutant in human HCC827 cells assessed as EGFR degradation measured after 24 hrs by Immunoblotting analysis | 2022 | Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
| Exploring Degradation of Mutant and Wild-Type Epidermal Growth Factor Receptors Induced by Proteolysis-Targeting Chimeras. |
| AID1881822 | Protac activity against VHL/EGFR L858R mutant in human HCC827 cells relative to control | 2022 | European journal of medicinal chemistry, Jan-05, Volume: 227 | VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives. |
| AID1582389 | Protac activity at VHL/EGFR L858R mutant in human H3255 cells assessed as reduction in EGFR autophosphorylation up to 10 uM treated 8 hrs post serum starvation measured after 16 hrs by Western blot analysis | 2020 | Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
| Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders. |
| AID1582441 | Antiproliferative activity against human H3255 cells measured after 3 days by CCK8 assay | 2020 | Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
| Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders. |
| AID1850524 | Thermodynamic solubility of the compound in phosphate buffer at pH 7 incubated for 1 hr by shake flask based HPLC-UV analysis | | | |
| AID1582390 | Protac activity at VHL/EGFR exon 19 deletion mutant in human HCC827 cells assessed as reduction in AKT phosphorylation up to 10 uM treated 8 hrs post serum starvation measured after 16 hrs by Western blot analysis | 2020 | Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
| Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders. |
| AID1582401 | Protac activity at VHL/EGFR L858R mutant in human H3255 cells assessed as induction of EGFR degradation at 1 to 10 uM treated 8 hrs post serum starvation measured after 16 hrs by Western blot analysis | 2020 | Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
| Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders. |
| AID1582391 | Protac activity at VHL/EGFR L858R mutant in human H3255 cells assessed as reduction in AKT phosphorylation up to 10 uM treated 8 hrs post serum starvation measured after 16 hrs by Western blot analysis | 2020 | Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
| Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders. |
| AID1904302 | Protac activity at VHL/EGFR deletion19 mutant in human HCC827 cells assessed as induction of EGFR degradation | 2022 | Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6
| Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |